Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial

医学 卡波扎尼布 内科学 彭布罗利珠单抗 耐受性 临床终点 肿瘤科 胃肠病学 头颈部鳞状细胞癌 实体瘤疗效评价标准 不利影响 无进展生存期 临床研究阶段 外科 头颈部癌 临床试验 化疗 癌症 免疫疗法
作者
Nabil F. Saba,Conor Steuer,Asari Ekpenyong,Ashley A. McCook‐Veal,Kelly R. Magliocca,Mihir R. Patel,Nicole C. Schmitt,William A. Stokes,James E. Bates,Soumon Rudra,Jill Remick,Mark W. McDonald,Marin Abousaud,Aik Choon Tan,Muhammad Zaki Hidayatullah Fadlullah,Ritu Chaudhary,Jameel Muzaffar,Kedar Kirtane,Yuan Liu,Georgia Z. Chen
出处
期刊:Nature Medicine [Nature Portfolio]
卷期号:29 (4): 880-887 被引量:75
标识
DOI:10.1038/s41591-023-02275-x
摘要

Anti-programmed cell death protein 1 (PD-1) therapy is a standard of care in recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). Vascular endothelial growth factor inhibitors, including tyrosine kinase inhibitors, have immunomodulatory properties and have offered promising results when combined with anti-PD-1 agents. We conducted a phase 2, multicenter, single-arm trial of pembrolizumab and cabozantinib in patients with RMHNSCC who had Response Evaluation Criteria in Solid Tumors v.1.1 measurable disease and no contraindications to either agent. We assessed the primary end points of tolerability and overall response rate to the combination with secondary end points of progression-free survival and overall survival and performed correlative studies with PDL-1 and combined positive score, CD8+ T cell infiltration and tumor mutational burden. A total of 50 patients were screened and 36 were enrolled with 33 evaluable for response. The primary end point was met, with 17 out of 33 patients having a partial response (52%) and 13 (39%) stable disease with an overall clinical benefit rate of 91%. Median and 1-year overall survival were 22.3 months (95% confidence interval (CI) = 11.7–32.9) and 68.4% (95% CI = 45.1%–83.5%), respectively. Median and 1-year progression-free survival were 14.6 months (95% CI = 8.2–19.6) and 54% (95% CI = 31.5%–72%), respectively. Grade 3 or higher treatment-related adverse events included increased aspartate aminotransferase (n = 2, 5.6%). In 16 patients (44.4%), the dose of cabozantinib was reduced to 20 mg daily. The overall response rate correlated positively with baseline CD8+ T cell infiltration. There was no observed correlation between tumor mutational burden and clinical outcome. Pembrolizumab and cabozantinib were well tolerated and showed promising clinical activity in patients with RMHNSCC. Further investigation of similar combinations are needed in RMHNSCC. The trial is registered at ClinicalTrials.gov under registration no. NCT03468218 . In a phase 2 trial of pembrolizumab and cabozantinib in patients with advanced head and neck cancer, a high clinical benefit rate was achieved, which positively correlated with levels of CD8+ T cell infiltration but not tumor mutational burden.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
典雅紫山发布了新的文献求助30
刚刚
斯文败类的应助被start采纳,获得10
刚刚
刚刚
目眩完成签到,获得积分10
刚刚
刚刚
MM发布了新的文献求助10
1秒前
1秒前
1秒前
June完成签到 ,获得积分10
1秒前
可爱的函函的应助被暴躁莹子采纳,获得10
1秒前
yuhanli完成签到,获得积分20
1秒前
三水发布了新的文献求助10
1秒前
西瓜汁完成签到,获得积分10
1秒前
哈哈完成签到 ,获得积分10
1秒前
Alvienan完成签到,获得积分10
2秒前
小马发布了新的文献求助10
2秒前
青黛发布了新的文献求助10
2秒前
领导范儿的应助被kuku采纳,获得10
2秒前
LQH完成签到,获得积分10
2秒前
传奇3的应助被WYL采纳,获得10
2秒前
2秒前
3秒前
3秒前
3秒前
李宇彤发布了新的文献求助10
3秒前
kidpan发布了新的文献求助10
3秒前
栗子完成签到 ,获得积分10
4秒前
4秒前
呱呱太完成签到,获得积分10
4秒前
2196186871完成签到,获得积分10
5秒前
molihuakai的应助被tang采纳,获得10
5秒前
Ankh完成签到,获得积分10
6秒前
ZZQ关闭了ZZQ的文献求助
6秒前
6秒前
LXJY完成签到,获得积分10
6秒前
hao完成签到,获得积分10
6秒前
CAOHOU的应助被橙梨苹采纳,获得10
6秒前
虎杖悠仁完成签到,获得积分20
6秒前
羊羊羊完成签到,获得积分10
6秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287